



Attorney Docket No.: 5390.200-US

PATENT

#4
8/2/00
SN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dörwald et al.

Application No.: 09/548,081 ✓

Group Art Unit: 1594

Filed: April 12, 2000 ✓

Examiner: TBA

For: Substituted Imidazoles, their Preparation and Use ✓

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. US 4,767,778
2. US 5,091,390
3. US 5,262,537
4. US 5,578,616
5. WO 91/17146



6. WO 92/15567
7. WO 92/18115
8. WO 93/12093
9. WO 93/12107
10. WO 93/12108
11. WO 93/14070
12. WO 93/20061
13. WO 94/17058
14. WO 95/06037
15. WO 95/11894
16. WO 95/14007
17. WO 96/38141
18. WO 96/38142
19. WO 96/40126
20. WO 98/29119
21. EP 0 197 840
22. EP 0 214 058
23. EP 0 338 939
24. EP 0 494 010
25. EP 0 499 521
26. EP 0 531 219
27. EP 0 531 874
28. EP 0 589 665
29. GB 2 158 440
30. DT 27 00 012
31. DE 33 02 125
32. DE 33 02 126
33. 1 524 481
34. 2 337 726
35. 6-312926
36. Williams et al., Journal of Pharmaceutical Sci., Vol. 71, No. 1, pp. 119-120 (Jan. 1982)
37. Piper et al., Can. J. Chem., Vol. 61, pp. 2721-2728 (1983)
38. Casella et al., J. Am. Chem. Soc., Vol. 103, pp. 6338-6347 (1981)
39. Nagarajan et al., Indian Journal of Chem., Vol. 15B, pp. 629-634 (July 1977)
40. Emmett et al., J. Med. Chem., Vol. 25, pp. 1168-1174 (1982)
41. Vitali et al., Chim. Ital., Vol. 94, pp. 296-305 (1964)
42. Arcari et al., Arzneimittel. Forschung, Vol. 34, pp. 1467-1471 (1984)
43. Habermehl et al., Heterocycles, Vol. 5, pp. 127-134 (1976)
44. Hepp et al., Arch. Pharm. (Weinheim), Vol. 313, pp. 756-762 (1980)
45. Arcari, et al., Chemical Abstract, Vol. 87, pp. 730-731 (1977)
46. Klutchko et al., J. Heterocyclic Chem., Vol. 28, pp. 97-108 (1991)
47. Lovenberg et al., Molecular Pharm., Vol. 55, pp. 1101-1107 (1999)
48. Leurs et al., Progress in Drug Research, Vol. 45, pp. 107-165 (1995)
49. Stark et al, Drugs of The Future, Vol. 21, No. 5, pp. 507-520 (1996)
50. Vitali et al., Farmaco Ed. Sci., Vol. 22, pp. 821-845 (1967)



RECEIVED

AUG 02 2000

TEC CENTER 1600/2300

It is respectfully requested that these references be considered by the Patent Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of the application or date of entry into the national stage of an international application or **before** the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. § 1.97(b). Therefore, no fee is due.

Respectfully submitted,

Date: July 25, 2000

Carol E. Rozek ✓

Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



Attorney Docket No.: 5390.200-US

CLT

GAU-574
1624

PATENT

RECEIVED

AUG 02 2000

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dörwald et al.

Application No.: 09/548,081

Group Art Unit: 1594

Filed: April 12, 2000

Examiner: TBA

For: Substituted Imidazoles, their Preparation and Use

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on July 25, 2000.

Miriam Kelly
(name of person mailing paper)

Miriam Kelly
(signature of person mailing paper)